Immunosign® Try our immune gene expression signatures

to investigate immune response

Immunosign® is another member of the Immunoscore® assay family. It consists in two different immune gene expression signatures: Immunosign 15 and Immunosign 21.

The immune gene expression enables status assessment of the adaptive immunity and immunosuppressive tumor micro environment. Within clinical trials, Immunosign 15 and Immunosign 21 can investigate prognostic and predictive information for cancer immunotherapy development and guide combination therapy strategy.


Immunosign® genes were selected by Dr Jerome Galon.

Proof-of-concept for prognostic and predictive values of Immunosign® 15/21 have been obtained on retrospective cohorts of colorectal cancer patients and have been validated on 9 other cancer types (Galon et al. Immunity 2013, and personal communication).

Immunosign® are performed on Nanostring nCounter®. A dedicated bioinformatics pipeline allows to report a comprehensive analysis of data obtained with Immunosign®. The results generated can be used in clinical trials leading to drug registration.

Scientific data

Posters presented by our partners at ASCO 2017 and SITC 2017:

Characterization of anti‑CD19 chimeric antigen receptor (CAR) T cell‑mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA‑1) with axica btagene ciloleucel (axi‑cel, KTE‑C19) (J.Galon et al)

  • Evaluation of Key Immune Pathways Within the Tumor Microenvironment
  • Characterizations of top Immunosign Genes Upregulated in Tumor Tissue Early Post–axi‑cel
  • Characterization of an immune gene signature in the tumor microenvironment early after
    Anti CD19 CAR T cell treatment
  • Co‑upregulation of immune checkpoints within the tumor microenvironment resulted from CAR T Cell treatment
  • Interplay between multiple complementary immune programs deployed by CAR T cells and the innate immunity (IL‑15) within the tumor environment to induce tumor responses

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study (J.Galon, F.Hermitte et al)

See ASCO 2017 poster on Lytix Biopharma website

See SITC 2017 poster on Lytix Biopharma website

  • Elevation of tumor infiltrating lymphocytes in injected lesions was observed in 14 of 19 (75%) evaluable patients.
  • The HalioDx Immune Gene Expression Signature Immunosign® 21 analysis of LTX-315 treated tumors shows:
    • Clear effect on key genes (effector T cell, Th1 orientation, chemokines, and cytokines) involved in the immune-mediated tumor regression.
    • LTX-315 demonstrates the ability to convert cold tumors hot in cancer patients.

Interested in Immunosign® ?

Contact us

Our IO Scoring Services